TetraLogic Pharmaceuticals Corporation TLOG

TLOG Company Overview

TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) was a U.S.-based clinical-stage biopharmaceutical company focused on developing therapeutics targeting cancer and certain blood disorders through modulation of apoptosis, the programmed cell death pathway. The company primarily operated in the oncology and hematology sectors, with its lead research efforts centered on small-molecule inhibitor of apoptosis protein (IAP) antagonists designed to restore apoptosis in cancer cells that had become resistant to conventional treatments.

The company’s principal product candidate was birinapant, an investigational bivalent SMAC mimetic developed for use in hematologic malignancies and solid tumors. TetraLogic positioned itself around the scientific premise that many cancers evade apoptosis through overexpression of IAPs, and that targeting this pathway could enhance sensitivity to chemotherapy or induce direct tumor cell death. Founded in 2005 and headquartered in Pennsylvania, United States, the company advanced multiple early-stage oncology programs before encountering financial and clinical setbacks. Following operational difficulties and restructuring efforts, the company ultimately ceased active operations and was delisted from Nasdaq after bankruptcy-related proceedings. Information regarding post-bankruptcy corporate activity is limited and partially inconclusive based on available public sources.